Literature DB >> 18227188

In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.

Delphine Desbois1, Bénédicte Roquebert, Gilles Peytavin, Florence Damond, Gilles Collin, Antoine Bénard, Pauline Campa, Sophie Matheron, Geneviève Chêne, Françoise Brun-Vézinet, Diane Descamps.   

Abstract

We determine phenotypic susceptibility of human immunodeficiency virus type 2 (HIV-2) isolates to amprenavir, atazanavir, darunavir, indinavir, lopinavir, nelfinavir, saquinavir, and tipranavir. Saquinavir, lopinavir, and darunavir are potent against wild-type HIV-2 isolates and should be preferred as first-line options for HIV-2-infected patients. Other protease inhibitors are less active against HIV-2 than against HIV-1.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18227188      PMCID： PMC2292533          DOI： 10.1128/AAC.01284-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy.

Authors:  B Rodés; A Holguín; V Soriano; M Dourana; K Mansinho; F Antunes; J González-Lahoz
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

2.  Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors.

Authors:  J Ren; L E Bird; P P Chamberlain; G B Stewart-Jones; D I Stuart; D K Stammers
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-17       Impact factor: 11.205

3.  HIV-2 protease sequences of subtypes A and B harbor multiple mutations associated with protease inhibitor resistance in HIV-1.

Authors:  Danuta Pieniazek; Mark Rayfield; Dale J Hu; John N Nkengasong; Vincent Soriano; Walid Heneine; Clement Zeh; Simon M Agwale; Charles Wambebe; Liliana Odama; Stefan Z Wiktor
Journal:  AIDS       Date:  2004-02-20       Impact factor: 4.177

4.  Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.

Authors:  Michel Ntemgwa; Bluma G Brenner; Maureen Oliveira; Daniela Moisi; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

5.  Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors.

Authors:  F Damond; F Brun-Vezinet; S Matheron; G Peytavin; P Campa; S Pueyo; F Mammano; S Lastere; I Farfara; F Simon; G Chene; D Descamps
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

6.  Natural polymorphisms of HIV type 2 pol sequences from drug-naive individuals.

Authors:  Ricardo Parreira; Filipa Monteiro; Elizabeth Pádua; João Piedade; Teresa Venenno; Maria Teresa Paixão; Aida Esteves
Journal:  AIDS Res Hum Retroviruses       Date:  2006-11       Impact factor: 2.205

7.  Ultra-high resolution crystal structure of HIV-1 protease mutant reveals two binding sites for clinical inhibitor TMC114.

Authors:  Andrey Y Kovalevsky; Fengling Liu; Sofiya Leshchenko; Arun K Ghosh; John M Louis; Robert W Harrison; Irene T Weber
Journal:  J Mol Biol       Date:  2006-08-04       Impact factor: 5.469

8.  Letter. In vitro phenotypic susceptibility to nucleoside reverse transcriptase inhibitors of HIV-2 isolates with the Q151M mutation in the reverse transcriptase gene.

Authors:  Florence Damond; Gilles Collin; Sophie Matheron; Gilles Peytavin; Pauline Campa; Séverine Delarue; Audrey Taieb; Antoine Bénard; Geneviève Chêne; Françoise Brun-Vézinet; Diane Descamps
Journal:  Antivir Ther       Date:  2005

9.  Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire.

Authors:  Christiane A Adjé-Touré; Rachanee Cheingsong; J Gerardo Garcìa-Lerma; Serge Eholié; Marie-Yolande Borget; Jean-Marc Bouchez; Ron A Otten; Chantal Maurice; Madeleine Sassan-Morokro; René E Ekpini; Monica Nolan; Terence Chorba; Walid Heneine; John N Nkengasong
Journal:  AIDS       Date:  2003-07       Impact factor: 4.177

10.  Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro.

Authors:  Yasuhiro Koh; Hirotomo Nakata; Kenji Maeda; Hiromi Ogata; Geoffrey Bilcer; Thippeswamy Devasamudram; John F Kincaid; Peter Boross; Yuan-Fang Wang; Yunfeng Tie; Patra Volarath; Laquasha Gaddis; Robert W Harrison; Irene T Weber; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191
View more
  47 in total

Review 1.  Combination nucleoside/nucleotide reverse transcriptase inhibitors for treatment of HIV infection.

Authors:  Maxwell O Akanbi; Kimberly K Scarsi; Kimberly Scarci; Babafemi Taiwo; Robert L Murphy
Journal:  Expert Opin Pharmacother       Date:  2012-01       Impact factor: 3.889

Review 2.  Antiretroviral drug resistance in human immunodeficiency virus type 2.

Authors:  Michel L Ntemgwa; Thomas d'Aquin Toni; Bluma G Brenner; Ricardo J Camacho; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2009-05-26       Impact factor: 5.191

3.  New Highly Sensitive Real-Time PCR Assay for HIV-2 Group A and Group B DNA Quantification.

Authors:  Mélanie Bertine; Marie Gueudin; Adeline Mélard; Florence Damond; Diane Descamps; Sophie Matheron; Fidéline Collin; Christine Rouzioux; Jean-Christophe Plantier; Véronique Avettand-Fenoel
Journal:  J Clin Microbiol       Date:  2017-07-12       Impact factor: 5.948

4.  Complex patterns of protease inhibitor resistance among antiretroviral treatment-experienced HIV-2 patients from Senegal: implications for second-line therapy.

Authors:  Dana N Raugi; Robert A Smith; Selly Ba; Macoumba Toure; Fatou Traore; Fatima Sall; Charlotte Pan; Lindsey Blankenship; Alexandra Montano; Julia Olson; Ndeye Mery Dia Badiane; James I Mullins; Nancy B Kiviat; Stephen E Hawes; Papa Salif Sow; Geoffrey S Gottlieb
Journal:  Antimicrob Agents Chemother       Date:  2013-04-09       Impact factor: 5.191

5.  The Nucleoside Analog BMS-986001 Shows Greater In Vitro Activity against HIV-2 than against HIV-1.

Authors:  Robert A Smith; Dana N Raugi; Vincent H Wu; Sally S Leong; Kate M Parker; Mariah K Oakes; Papa Salif Sow; Selly Ba; Moussa Seydi; Geoffrey S Gottlieb
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

6.  New sensitive one-step real-time duplex PCR method for group A and B HIV-2 RNA load.

Authors:  Véronique Avettand-Fenoel; Florence Damond; Marie Gueudin; Sophie Matheron; Adeline Mélard; Gilles Collin; Diane Descamps; Marie-Laure Chaix; Christine Rouzioux; Jean-Christophe Plantier
Journal:  J Clin Microbiol       Date:  2014-06-11       Impact factor: 5.948

Review 7.  Update on human immunodeficiency virus (HIV)-2 infection.

Authors:  Omobolaji T Campbell-Yesufu; Rajesh T Gandhi
Journal:  Clin Infect Dis       Date:  2011-03-15       Impact factor: 9.079

8.  Genotypic resistance profiles of HIV-2-treated patients in West Africa.

Authors:  Charlotte Charpentier; Serge Eholié; Xavier Anglaret; Mélanie Bertine; Christine Rouzioux; Véronique Avettand-Fenoël; Eugène Messou; Albert Minga; Florence Damond; Jean-Christophe Plantier; François Dabis; Gilles Peytavin; Françoise Brun-Vézinet; Didier K Ekouevi
Journal:  AIDS       Date:  2014-05-15       Impact factor: 4.177

9.  Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa.

Authors:  Geoffrey S Gottlieb; Ndeye Mery Dia Badiane; Stephen E Hawes; Louise Fortes; Macoumba Toure; Cheikh T Ndour; Alison K Starling; Fatou Traore; Fatima Sall; Kim G Wong; Stephen L Cherne; Donovan J Anderson; Stefanie A Dye; Robert A Smith; James I Mullins; Nancy B Kiviat; Papa Salif Sow
Journal:  Clin Infect Dis       Date:  2009-02-15       Impact factor: 9.079

Review 10.  Atazanavir: its role in HIV treatment.

Authors:  Robin Wood
Journal:  Expert Rev Anti Infect Ther       Date:  2008-12       Impact factor: 5.091
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.